ADVERTISEMENT
Interview
Isatuximab Plus Carfilzomib and Dexamethasone Improves PFS in Multiple Myeloma
07/20/2022
Marcelo Capra, MD, Centro de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil, discusses results from a study comparing the benefit of progression-free survival associated with isatuximab in combination with carfilzomib and dexamethasone vs carfilzomib and dexamethasone among patients with relapsed/refractory multiple myeloma previously treated with one to three lines of therapy.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Current Issue
June 2024
Volume 10
Issue 3
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Subscribe
Journal of Clinical Pathways Newsletter
Advertisement
Advertisement
Advertisement
Recent Stories
Advertisement